Cambridge Healthtech Institute’s 2nd Annual

PROTACs and Targeted Protein Degradation – Part 1

Emerging Protein Degradation Pathways

September 16-17, 2020


The ubiquitin-proteasome system (UPS) and the autophagy-lysosome system are the two major pathways responsible for protein degradation and maintenance of proteostasis. They consist of well-controlled, selective mechanisms for intracellular protein degradation and turnover. However, the diversity and complexity of the processes involved make it difficult to target these pathways for therapeutic intervention. The development of high-quality chemical probes, small molecule modulators, assays, and screening platforms have helped identify various UPS and autophagy targets, as well as novel chemical and biological degrades for discovery and therapeutic applications. Cambridge Healthtech Institute’s conference on PROTACs and Targeted Protein Degradation will bring together chemists, biologists, and pharmacologists to discuss the promises and challenges that lie ahead.

The UPS and autophagy pathways hold a lot of promise in seeking out previously “undruggable” targets and for therapeutic intervention. The first part of the PROTACs and Targeted Protein Degradation conference will focus on identifying different ligases, chaperone proteins, deubiquitinating enzymes (DUBs), and proteins that can be modulated for hijacking the ubiquitin-proteasome and autophagy-driven protein degradation.

Preliminary Agenda


A Platform to Fully Exploit the Cell's Quality Control Machinery for Therapeutic Benefit

Laura Itzhaki, PhD, Professor of Structural Pharmacology, Department of Pharmacology, University of Cambridge; CSO, PolyProx Therapeutics

Establishing a Screening Toolkit to Guide Rational PROTAC Optimization

Claire Whitworth, PhD, Cell Biologist, Laboratory of Dr. Alessio Cuilli, ACBI Team, Division of Biological Chemistry & Drug Discovery, Dundee University

Chemical Tools to Discover E3 Ligase Inhibitors

Alexander Statsyuk, PhD, Assistant Professor, Department of Pharmacological and Pharmaceutical Sciences, University of Houston

Immediate and Selective Protein Control Using the dTAG System

Behnam Nabet, PhD, Post-Doctoral Fellow, Laboratory of Dr. Nathanael Gray, Dana Farber Cancer Institute

Tools for Characterizing PROTACs Methods of Action

Dahmane Ouazia, PhD, Assistant Director, Business Development, LifeSensors, Inc.


Protein Connectivity-Based Dysfunctions (PCBD) Mediated by Maladaptive Epichaperomes

Gabriela Chiosis, PhD, Member and Tri-Institutional Professor, Sloan Kettering Institute for Cancer Center, Cornell University and The Rockefeller University

MAGE Family of Cancer-Specific Ubiquitin Ligases

Ryan Potts, PhD, Associate Member, Department of Cell and Molecular Biology, St. Jude Children’s Research Hospital

Development of Hsp90 Inhibitors That Induce Protein Degradation or Protein Folding for the Treatment of Cancer or Neurodegenerative Diseases

Brian Blagg, PhD, Charles Huisking Professor of Chemistry and Biochemistry; Director, Warren Center for Drug Discovery, Department of Chemistry and Biochemistry, University of Notre Dame


An Affinity-Directed PROtein Missile (AdPROM) System for Targeted Modification of Intracellular Proteins

Gopal Sapkota, PhD, Programme Leader, MRC Protein Phosphorylation & Ubiquitylation Unit, Sir James Black Centre, School of Life Sciences, University of Dundee

Large-Scale Proteomics Approaches to Enable Degrader Development for Challenging Targets in Cancer

Katherine Donovan, PhD, Scientist, Laboratory of Dr. Eric Fischer, Cancer Biology, Dana-Farber Cancer Institute/Harvard Medical School

Chemoproteomic Approaches to Interrogate the Degradable Kinome

Fleur Ferguson, PhD, Research Fellow, Cancer Biology, Dana-Farber Cancer Institute, Biological Chemistry and Molecular Pharmacology, Harvard Medical School

Please click here to continue to the agenda for PROTACs and Targeted Protein Degradation – Part 2

For more details on the conference, please contact:
Tanuja Koppal, PhD

Senior Conference Director

Cambridge Healthtech Institute



For partnering and sponsorship information, please contact:
Rod Eymael

Manager, Business Development

Cambridge Healthtech Institute

Phone: (+1) 781-247-6286